MOA Visual

Introducing ROLVEDON™:

  • Novel formulation combines a granulocyte colony-stimulating factor (G-CSF) analog with an Fc fragment of human immunoglobulin G4 (IgG4)2
  • Supported by a complete innovator biopharmaceutical development program

Selected Safety Information

Serious Allergic Reactions

  • Serious allergic reactions, including anaphylaxis, can occur in patients receiving rhG-CSF products. Permanently discontinue ROLVEDON in patients who experience serious allergic reactions.

FcRn facilitates ROLVEDON transcytosis3

FcRn facilitates ROLVEDON transcytosis visual
  • It has been shown in:
    • in vitro studies2:
      • To bind the neonatal Fc receptor (FcRn), which facilitates transcytosis
    • in vivo animal studies:
      • To facilitate uptake and retention of G‑CSF in the bone marrow
  • The clinical significance of these findings is unknown

Watch MOA video

Eflapegrastim‑xnst is a recombinant human granulocyte growth factor that binds to G-CSF receptors on myeloid progenitor cells and neutrophils, triggering signaling pathways that control cell differentiation, proliferation, migration, and survival.2

MOA=mechanism of action.


  1. Schwartzberg LS, Bhat G, Peguero J, et al. Eflapegrastim, a long-acting granulocyte-colony stimulating factor for the management of chemotherapy-induced neutropenia: results of a phase III trial. Oncologist. 2020;25(8):e1233-e1241.
  2. ROLVEDON [package insert]. Irvine, CA: Spectrum Pharmaceuticals, Inc.
  3. Barrett J, et al. Eflapegrastim's enhancement of efficacy compared with pegfilgrastim in neutropenic rats supports potential for same-day dosing. Experimental Hematology 2020;92:51-61.

ROLVEDON is administered via a single subcutaneous dose